Navigation
-
Advaxis Approved to Receive Cash Allocation Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
-
Advaxis Signs Exclusive Licensing Agreement for Development and Commercialization of ADXS-HPV in Asia
-
Advaxis Cancer Immunotherapy Featured on ABC News
-
Advaxis Announces Initiation of Phase 1/2 Trial of ADXS-HPV in Head and Neck Cancer Conducted by Icahn School of Medicine at Mount Sinai
-
Advaxis Reports Final 18-Month Survival Data for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 Society for Immunotherapy of Cancer Annual Meeting
-
Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer
-
Advaxis Appoints Gregory T. Mayes as Chief Operating Officer
-
Advaxis Announces First Patient Dosed with ADXS-HPV in Head and Neck Cancer Study
-
Advaxis Announces Closing of Public Offering of Common Stock and Warrants
-
Advaxis Announces Full Exercise of Underwriters’ Over-Allotment Option
